Bone marrow stromal cells from multiple myeloma patients uniquely induce bortezomib resistant NF-κB activity in myeloma cells
© Markovina et al; licensee BioMed Central Ltd. 2010
Received: 19 January 2010
Accepted: 6 July 2010
Published: 6 July 2010
Components of the microenvironment such as bone marrow stromal cells (BMSCs) are well known to support multiple myeloma (MM) disease progression and resistance to chemotherapy including the proteasome inhibitor bortezomib. However, functional distinctions between BMSCs in MM patients and those in disease-free marrow are not completely understood. We and other investigators have recently reported that NF-κB activity in primary MM cells is largely resistant to the proteasome inhibitor bortezomib, and that further enhancement of NF-κB by BMSCs is similarly resistant to bortezomib and may mediate resistance to this therapy. The mediating factor(s) of this bortezomib-resistant NF-κB activity is induced by BMSCs is not currently understood.
Here we report that BMSCs specifically derived from MM patients are capable of further activating bortezomib-resistant NF-κB activity in MM cells. This induced activity is mediated by soluble proteinaceous factors secreted by MM BMSCs. Among the multiple factors evaluated, interleukin-8 was secreted by BMSCs from MM patients at significantly higher levels compared to those from non-MM sources, and we found that IL-8 contributes to BMSC-induced NF-κB activity.
BMSCs from MM patients uniquely enhance constitutive NF-κB activity in MM cells via a proteinaceous secreted factor in part in conjunction with IL-8. Since NF-κB is known to potentiate MM cell survival and confer resistance to drugs including bortezomib, further identification of the NF-κB activating factors produced specifically by MM-derived BMSCs may provide a novel biomarker and/or drug target for the treatment of this commonly fatal disease.
The non-cancerous cells associated with tumors were recognized more than three decades ago to play considerable roles in tumor development, progression and maintenance . Since then, there has been a significant effort to delineate the specific contributions of these cells to malignant cell behaviors. More specifically, numerous recent studies have found that these supportive cells, although not cancerous per se, are functionally and sometimes genetically different from their normal counterparts . Studies done in the nineties like those by Cunha and colleagues in prostate cancer , and Bissell and colleagues in breast cancer  have helped to widen the focus of cancer researchers from just the tumor cells to considering also the components around them. As a result of this work, several cancer therapies have been engineered specifically to target interactions between tumor cells and their surrounding stroma .
Malignant plasma B cells characteristic of multiple myeloma (MM) are also believed to rely heavily on their interactions with elements of the surrounding microenvironment, including osteoclasts, osteoblasts, endothelial cells, macrophages and bone marrow stromal cells (BMSCs) . Direct adhesive interactions between BMSCs and myeloma cells, as well as BMSC secretion of cytokines, chemokines, growth factors and other components, contribute to a symbiotic cycle which maintains a myeloma-promoting microenvironment and allows the tumor cells to thrive. These bidirectional interactions disrupt the normal hematopoietic process, induce osteolytic destruction of the bone, and contribute to resistance to conventional therapies . For example, BMSC production of matrix proteins and factors such as fibronectin , insulin-like growth factor-1 (IGF-1) , stromal derived factor 1 alpha (SDF-1) , tumor necrosis factor alpha (TNF-α), B cell activating factor family (BAFF), and a proliferation inducing ligand (APRIL)  have all been shown to promote MM cell proliferation and resistance to conventional chemotherapeutic agents. These discoveries have contributed to the development of several recently approved targeted therapeutics, such as the proteasome inhibitor bortezomib, and lenalidomide, that are believed to exert their anti-MM effects at least in part by disrupting the interactions between MM cells and the other cells in tumor microenvironment [5, 9].
MM is a complex and heterogeneous disease with respect to clinical manifestations and drug responses. Cytogenetic analyses and gene expression profiling studies further demonstrated the heterogeneity of MM cells in different patients [10–14]. It remains unclear how much of this complexity is due to differences in MM-BMSC interactions in vivo. Several studies comparing a small number of BMSCs from MM patients versus healthy donors suggested that these non-malignant support cells were not significantly different [15–17]. Accordingly, it is generally considered that BMSCs affect MM cells similarly, regardless of their specific sources. However, analyses of a more extensive sampling of MM and normal BMSCs exposed some important functional and phenotypic distinctions of MM BMSCs [18–23]. In particular, Wallace et al compared BMSCs from 8 MM patients and 9 normal healthy donors and found increased expression of both IL-1β and TNF-α by MM BMSCs . Arnulf and colleagues analyzed BMSCs from 56 MM patients and 13 normal healthy donors and found that BMSCs from MM patients not only secreted higher levels of IL-6 than their normal counterparts, but also displayed an impaired ability to inhibit T cell proliferation in functional studies . MM BMSCs have also been described to differentially express 145 distinct genes, about half of which are involved in tumor-stroma cross-talk, induce higher proliferation of a MM cell line, and are impaired in their ability to differentiate into osteoblasts . Garayoa and colleagues recently analyzed BMSCs from 21 MM patients and 12 normal bone marrows for the presence of unbalanced genomic alterations. They found that while all 12 normal BMSCs were free from genomic alterations, BMSCs from 7 of the 21 MM patients displayed large gains or losses, indicating that these cells are also often distinct from their normal counterparts on a global genetic level . Nonetheless, our understanding of the functional distinctions between BMSCs of diseased and non-diseased bone marrow is still incomplete.
The Rel/NF-κB family of transcription factors has been shown to play a pivotal role in the pathogenesis of many human cancers, including MM [12, 26, 27]. NF-κB is constitutively active to variable levels in primary and established MM cells, and has been shown to further increase in activity in response to a number of factors found in the bone marrow microenvironment [10, 11, 28, 29]. For example, adhesion of myeloma cell lines to fibronectin results in increased NF-κB DNA-binding and correlates with induction of NF-κB-regulated genes . IGF-1, which is secreted into the bone marrow milieu, induces NF-κB activity in MM cells, and inhibition of IGF-1 binding to its receptor induces apoptosis of MM cells . Similarly, SDF-1 induces transient NF-κB DNA-binding activity in some primary MM cells . Other well-known NF-κB inducers including TNF-α, IL-1β, BAFF, and APRIL are also present in the bone marrow .
NF-κB activation typically relies on two major pathways, canonical and noncanonical, involving degradation and processing of the inhibitor IκB and the precursor p100, respectively, via the ubiquitin-dependent proteasome pathway . As such, both constitutive and inducible NF-κB activity in MM cells is generally believed to be highly sensitive to inhibition by the proteasome inhibitor bortezomib. This NF-κB inhibitory activity of bortezomib has been largely implicated in the clinical efficacy of this drug against MM and another B cell malignancy, Mantle Cell Lymphoma (MCL) . In contrast to this view, we and others have recently shown that constitutive activity in primary MM cells is largely resistant to bortezomib [32, 33]. Similarly, we also found that constitutive NF-κB activity in many primary MCL samples also showed bortezomib-resistance . These studies indicated that primary MM and MCL, and possibly other cancer cell types, may behave differently than expected from cell line-based studies. Since NF-κB activity in MM is also dependent on the bone marrow milieu, whether NF-κB activation in primary MM cells through many of these microenvironment interactions is effectively prevented by bortezomib still remains an open question.
We previously showed that BMSCs generated from a few MM patients induced NF-κB activity in some primary and established MM cells. This activation is largely resistant to bortezomib and confers resistance to bortezomib-induced apoptosis . In the present study, we expanded this analysis by examining BMSCs derived from marrows of a cohort of MM patients and those without MM pathology. Collectively, we found that MM-associated BMSCs are functionally different from non-MM BMSCs in their ability to induce bortezomib-resistant NF-κB activity in MM cells.
BMSCs from MM patients are functionally distinct in their ability to activate NF-κB in MM cells
Co-culture experiments with primary MM cells from one patient and BMSCs from another patient assumedly introduces unknown variables. Nevertheless, we were interested to see if this differential ability of MM-derived BMSCs to activate NF-κB activity was also true in primary MM cells. To control for the variability in constitutive NF-κB activity between patients, the change in NF-κB activity after co-culture was normalized to the level of constitutive activity in the MM cells from the same patient, and all values were normalized to Oct-1 DNA-binding. These analyses demonstrated that BMSCs often activated NF-κB in primary MM (Figure 1F) but those from normal marrow frequently did not (Additional File 2). However, the heterogeneity of inter-patient experiments (i.e., the sources of MM cells and BMSCs coming from different patients) or small sample size failed to show statistical significance for the observed differences. As previously shown [32, 33], bortezomib treatment often caused paradoxical increases in NF-κB activity in primary MM cells, showing that bortezomib-induced NF-κB activation, rather than inhibition, is a more common phenomenon, even in the presence of MM BMSCs (Figures 1F).
MM BMSC-induced NF-κB activity is mediated by a polypeptide(s) secreted by BMSCs
A number of BMSC-produced protein factors have been shown to be important in MM pathogenesis, some of which can activate NF-κB in MM cells. Therefore, we wanted to know whether a factor (or factors) well-known to be produced by MM BMSCs was mediating bortezomib-resistant NF-κB activation in MM cells. To this end, a neutralizing antibody against TNFα, which was capable of blocking NF-κB activity induced by recombinant TNF-α in MM cells, did not block BMSC-induced NF-κB activity (Additional File 3A). This is consistent with the observation that TNF-α-induced canonical NF-κB activation is highly sensitive to inhibition by bortezomib in contrast to the factor that we were aiming to identify. SDF-1α (CXCL12), a factor that is believed to contribute to the maintenance of MM cells in the bone marrow, as well as to drug resistance and proliferation of the tumor cells , did not induce NF-κB activity in RPMI8226 cells (Additional File 3B). Additionally, a neutralizing antibody against SDF-1α also did not block BMSC-induced NF-κB DNA-binding activity in these cells (Additional File 3B). Similarly, a neutralizing antibody against IGF-1 receptor, whose ligation by IGF-1 has been shown to activate NF-κB in certain MM samples , had no effect on BMSC-induced NF-κB activity in RPMI8226 cells (Additional File 3B). Moreover, IL-6, another important factor in MM growth and survival, which is secreted at very high levels by BMSCs , also did not affect NF-κB activation in RPMI8226 cells (Additional File 3C).
BAFF and APRIL have been shown to be important in MM pathogenesis and can stimulate noncanonical NF-κB activation; however, we found that neither the levels of BAFF and APRIL mRNA or protein secreted from BMSCs correlated with their ability to induce NF-κB (Additional File 3D). In fact, APRIL protein levels were statistically significantly higher in the normal BMSC group (Additional File 3D). Collectively, these data indicate that the factor produced by MM BMSCs that is responsible for bortezomib-resistant NF-κB activation is likely distinct from these well-known BMSC products.
IL-8 is a permissive factor for NF-κB activation in MM cells induced by some MM-BMSCs
The tumor microenvironment is thought to participate in many aspects of human cancer. In MM, BMSCs and the factors and matrix that they produce are important in tumor cell proliferation and drug resistance. NF-κB has been implicated in this dynamic MM cell-stromal communication and several components along the NF-κB signaling pathway are frequent targets of genetic modification leading to constitutive activity in MM cells [10, 11], further supporting the important role that this signaling system plays in MM pathogenesis. In addition, NF-κB activation in non-malignant BMSCs leads to increased expression of cytokines and growth factors such as IL-6, TNF-α, and VEGF , which can further increase NF-κB activity in MM cells. This NF-κB activation in both MM cells and BMSCs is proposed to create positive feedback loops to promote symbiotic interactions and survival of MM cells in the bone marrow. However, BMSCs from MM patients are generally considered to be indistinct from those in a normal healthy individual, with the potential consequence of overlooking novel drug targets and/or markers of disease that are features specifically of MM-BMSCs.
We have previously shown that BMSCs from MM patients variably activate NF-κB in several MM cell lines and primary MM cells in a manner that is resistant to bortezomib. In the present study we addressed how BMSCs from MM patients and normal marrow differentially affect NF-κB activity in MM cells. We employed the MM cell line RPMI8226 to examine the functional difference between a large cohort of patient-derived MM and non-MM BMSCs. MM-BMSCs were found to cause NF-κB activation in these cells with a strong statistical significance over those from morphologically normal marrow. The NF-κB-inducing activity of the BMSC cultures did not change over 8 passages in culture. This indicated that the phenotype of BMSCs with respect to this functionality is quite stable in culture and therefore reflects an intrinsic property, rather than dependence on continual interaction with primary MM cells. Thus, our study represents the first instance in which MM-BMSCs were shown to possess an intrinsic and stable difference from those of non-myeloma marrow with respect to activation of NF-κB.
The more consistent expression of CD54 (ICAM-1) on MM BMSCs is of unknown significance. Noborio-Hatano and colleagues showed that downregulation of CD54 expression on MM cells using short-hairpin RNA decreased cell-adhesion mediated drug resistance of MM cells to bortezomib . It is possible, in a similar sense, that disrupting the ICAM-1 (on BMSCs) -LFA-4 or -Mac-1 (on MM cells) interaction could also lead to increased susceptibility of MM cells to bortezomib. More extensive studies are required to test this hypothesis.
To extend our findings with MM cell lines, we also analyzed the effect of various BMSCs on primary MM cells isolated from different patients and found a trend analogous to RPMI8226 cells. These primary cell studies were complicated, however, by multiple confounders. First, constitutive levels of NF-κB activity in primary MM cells are quite variable from patient to patient. Thus, if MM cells from a given patient have nearly undetectable NF-κB activity, any increase in DNA-binding will manifest in a large fold-change. In contrast, a small increase in MM cells that already harbor a very high basal activity might have a significant functional impact even though the fold-change may seem inconsequential when represented graphically. Second, the current experimental set up necessitates that primary MM cells from one patient are placed on BMSCs derived from another patient, i.e., "inter-patient" analysis. This design introduces an unknown level of complexity, which can only be avoided by performing "intra-patient" experiments. Currently, intra-patient experiments require cryopreservation of primary MM cells during the derivation of BMSCs from the same patient, a process which takes weeks beyond the viability of primary MM cells in culture. Finally, the unknown effect of chemotherapeutic agents on the microenvironment, and the heterogeneity of the biopsy material, due to factors such as location and timing during treatment on MM and BMSC sampling introduce additional confounding complexities to such analyses. Therefore, one of the major future challenges is to develop strategies to overcome such logistical issues and develop intra-patient experimental strategies to further reveal mechanisms relevant to individual MM patients at different points in their treatment course. We also were not able to correlate our findings in any way to patient characteristics, disease stage, or response to therapy because the samples used in these studies were collected under an IRB-exempt protocol. Future studies will be performed with samples that have accompanying patient information in order to obtain maximal insight about MM pathology.
NF-κB is thought to have a significant role in MM pathogenesis, and we have shown that bortezomib-resistant NF-κB activity correlates with cellular resistance to bortezomib in vitro . Therefore, identification of a novel factor(s) produced by BMSCs that activates this transcription factor could potentially provide a novel biomarker or therapeutic target. Although key components found in the marrow, such as TNF-α, SDF-1, IGF-1, IL-6, BAFF, and APRIL, are involved in MM pathogenesis, we did not find evidence that these factors were necessary for BMSC-induced, bortezomib-resistant NF-κB activity in MM cells. Some of these (IL-1β, TNF-α, IL-6, and IL-8) have been described to be produced at significantly higher levels by MM BMSCs than their normal counterparts [18, 20–22]; however, cytokine array analysis of our BMSC cohorts detected a statistically significant difference of only IL-8. A recent study comparing production of IL-8 by BMSCs derived from patients with monoclonal gammopathy of undetermined significance (MGUS), an asymptomatic disease of increased immunoglobulin secretion by plasma cells, smoldering MM, or active MM, found that IL-8 levels correlated positively with disease state . In addition to its pro-angiogenic effects in MM , our data suggest the possibility that IL-8 is also a contributing factor to increase NF-κB activity in some patients. Although our cytokine array data suggest that the majority of soluble IL-8 is being secreted by BMSCs, MM cells themselves can secrete IL-8 and may contribute to this phenomenon in an autocrine fashion.
MM-BMSCs are producing an additional factor (or factors) that together results in a strong signal to activate NF-κB in MM cells. This does not require direct contact between BMSCs and MM cells. The responsible factor(s) is sensitive to treatment with proteinase K and heat, and can be concentrated with a 3 kDa cut-off, suggesting that the factor(s) is a polypeptide of greater than 3 kDa. Because this BMSC-secreted factor causes NF-κB activation in MM cells in a manner resistant to bortezomib , this would also represent the first known factor to induce proteasome inhibitor resistant (PIR) NF-κB activation in MM cells. The signal transduction pathway leading to PIR NF-κB activation in B cells is not completely understood, although we have described several critical events, including the role of calcium and calmodulin [41–43]. Efforts to isolate and identify the responsible factor from MM patient BMSCs were limited by their heterogeneity and the limited amount of conditioned media obtained from these cells. Therefore, we employed an H1-ESC-derived MSC line which also produces a factor (or factors) that caused bortezomib-resistant NF-κB activity in MM cells for initial purification studies. We were able to enrich this factor by ion exchange chromatography. Further purification steps are required to distil and identify the responsible factor(s).
Our findings and others' indicate that the BMSCs in patients with MM are functionally distinct from those in normal marrow, the implications of which are not fully understood. Because of the differentially ability of MM BMSCs to uniquely induce the bortezomib-resistant NF-κB pathway, we have reason to believe that further investigating into exactly how BMSCs differ in MM patients could lead to improved understanding of MM and therefore improved treatment of MM patients. Identification of the MM BMSC factor would not only permit further dissection of this putatively novel NF-κB signaling pathway in MM, but also could provide useful markers for drug resistance and/or potential drug targets to be used in conjunction with targeted therapies such as bortezomib and lenalidomide. Because we also observed a similar NF-κB-inducing activity in some BMSCs derived from MCL patients and bortezomib-resistant activity is also prevalent in primary MCL samples , such a factor could also play a role in promoting MCL pathogenesis. Thus, our significant future goal is to molecularly identify this factor (or factors) and examine its role in MM and MCL pathologies.
Cell lines, antibodies, and chemicals
The RPMI8226 cell line was cultured as previously described . Bortezomib was commercially obtained from Millennium Pharmaceuticals, Inc. (Cambridge, MA) for experimental purposes, proteinase K was from Promega (Fitchburg, WI), and human recombinant TNF-α from Calbiochem (San Diego, CA). Recombinant human SDF-1, IL-8, IL-6, anti-SDF-1 and anti-IL-8 neutralizing antibodies were from R&D systems (Minneapolis, MN). Anti-IGF-1R neutralizing antibody was from Calbiochem (Darmstadt, Germany), and anti-TNF-α antibody from Chemicon International (Temecula, CA).
Primary BMSCs and MM Cells
Primary human BMSCs were derived from de-identified fresh whole bone marrow aspirates, under the University of Wisconsin Institutional Review Board exemption protocol #M-2004-1315. MM patients had active disease at the time of sampling, and "non-MM" patients were determined to have morphologically normal marrow by UW pathologists. Because the protocol by nature precludes collection of any identifying information, the samples collected were only accompanied by diagnosis, and no information regarding disease stage, treatment history or treatment response. Mononuclear cells were isolated from aspirates as detailed in the Miltenyi MidiMACS bone marrow mononuclear cell protocol and as described previously . Mononuclear cells isolated from MM patient bone marrow aspirates were positively sorted using anti-CD138 magnetic microbeads and the MidiMACS cell sorting system following manufacturer's protocol (Miltenyi Biotec, Auburn, CA) to >95% purity as determined by anti-CD138-PE staining and FACS analysis, and cultured in 37°C/5%CO2 incubators in BMSC media.
Human ESC-derived MSCs
MSCs were derived from the H1 human embryonic stem cell (ESC) line as previously described . These cells were cultured in αMEM media (Invitrogen, Carlsbad, CA, USA) containing 20% fetal bovine serum, 0.1 mM nonessential amino acid (NEAA), and 2 mM L-glutamine (glu). For collection of CM, H1-ES-MSCs were cultured in phenol red-free αMEM media supplemented with only 0.1 mM NEAA and 2 mM glu.
Co-culture, transwell, and conditioned media (CM) assays
6 × 104 BMSCs per well were plated in 6-well dishes and allowed to form an adherent monolayer over 24 hours. 106 RPMI8226 cells or 5 × 105 primary MM cells were plated over the monolayer for an additional 24 hours and then MM cells were mechanically detached from the stromal layer. The BMSC monolayer was undisturbed. Where appropriate, 100 nM bortezomib was added for the last 4 hours of co-culture. Neutralizing antibodies and/or recombinant proteins were added at the initiation of co-culture and, in the case of neutralizing antibodies, were pulsed every 6 hours for the duration of co-culture.
For transwell experiments, a monolayer of BMSCs was plated as described above, the Transwell insert (BD Biosciences, San Jose, CA) was placed over the BMSCs, and RPMI8226 cells placed within the insert.
BMSC CM was prepared by first washing pre-established BMSCs twice with 1× PBS then incubating them in serum free "BMSC media" for 48 hours. This media was clarified by centrifugation at 13,000 × g for 1 minute. CM was concentrated using Amicon Ultra Centrifugal Filter Devices with a 3 kDa molecular weight cut off according to manufacturer's instructions (Millipore, Billerica, MA), treated with 200 μg/mL proteinase K at 37°C for one hour followed by deactivation with 0.1 mM phenylmethylsulphonyl fluoride, or heated to 100°C for 30 minutes and then centrifuged for one minute at 13,000 × g.
Partial enrichment of human ESC-derived MSC-induced factor
Conditioned media was prepared by culturing a confluent monolayer of human ESC-MSCs between 4 and 10 passages, washing the monolayer 2× with 1× PBS, and culturing the cells in serum-free, phenol-red free αMEM media with L-glutamine, penicillin/streptomycin, sodium bicarbonate and non-essential amino acids. After 48-72 hours, this conditioned media was aspirated and centrifuged at 10,000 × g for 5 minutes to remove cellular debris. A portion of the albumin (likely human, produced by the MSCs) was removed using Affigel Blue (Bio-Rad) resin at 1:20 dilution by stirring at 4 degrees for one hour, which did not appreciably affect NF-κB-inducing activity (data not shown). The conditioned media was again centrifuged at 10,000 × g for 5 minutes and vacuum filtered over a PVDF membrane with 2 μm pores to remove resin and air bubbles. After equilibration at 4 degrees, the conditioned media was run onto a 1.0 mL Mono Q 5/50 GL (GE Life Sciences) anion exchange column (IEX) at ~1.5 MPa with 20 mM TRIS-HCl, pH 8.0 starting buffer to bind cationic molecules, using a benchtop ÄKTA FPLC (Amersham) at 4°C. Bound material was then eluted using a linear salt gradient from 0-0.5 M NaCl over 30 column volumes, and 1.0 mL fractions were collected and assayed for NF-κB-inducing activity by treating RPMI8226 cells with fractions at a 1:50 dilution in serum free media for 24 hours and performing EMSA.
Electrophoretic mobility shift assays (EMSA)
EMSA for cell lines were performed as described previously , using double strand DNA probes with the following sequences: κB: 5'-TCAACAGAGGGACTCCGAGAGGCC-3', Oct-1 , and STAT3: 5'-CGGGAGGGATTTACGGGAAATGCTA-3'. For primary MM cells, miniaturized EMSA ("mini-EMSA") was performed as previously described . Briefly, approximately 100,000 CD138+ cells were lysed in 5 μL of Totex extraction buffer and 1.5 μL of this extract were used for each reaction in NF-κB and Oct-1 DNA-binding assays. NF-κB binding was normalized to Oct-1 binding to control for equal protein loading.
κB-dependent reporter assay was performed as described previously .
Quantitative real-time reverse transcriptase-polymerase chain reaction (qRT-PCR) and enzyme-linked immunosorbent assay (ELISA)
For BAFF and APRIL ELISA assays, CM was collected from BMSCs as described above, and frozen for later batch comparison. 50 μL aliquots of CM were thawed on ice, aliquoted in duplicate into a 96-well instant BAFF ELISA plate, or APRIL ELISA plate (Bender MedSystems, Burlingame, CA), and processed according to manufacturer's instructions.
Total RNA was collected from 105 BMSCs from each patient using Trizol reagent (Invitrogen, Carlsbad, CA), used to make cDNA, and qRT-PCR performed on a BioRad iQ5, with the following primers: BAFF: 5'-GGGAGCAGTCACGCCTTAC-3' (forward), 5'-CTGGGGAGGATGGAAACACAC-3' (reverse); APRIL: 5'-CTCTGCTGACCCAACAAACAG-3' (forward), 5'-TTTTCCGGGATCTCTCCCCAT-3' (reverse); GAPDH: 5'-GAAGGTCGGAGTCAACGGATTT-3' (forward), 5'-GAATTTGCCATGGGTGGAAT-3' (reverse).
CM from BMSCs was prepared as described above and kept frozen at -80°C for later batch comparison. Aliquots of CM were thawed on ice and placed in duplicate into a 96-well dish, and concentrations of 27 human cytokines included in the Human 27-Plex Panel (Bio-Rad, Hercules, CA, USA) were measured in each well using the Luminex fluorescent bead-based multiplex cytokine assay system (Bio-Rad, Hercules, CA, USA) according to the manufacturer's instructions. Data were analyzed with the Bio-Plex Manager software program.
Antibodies used were anti-CD31 Allophycocyanin (APC), anti-CD45 Phycoerythrin (PE), anti-CD90 APC (eBioscience, San Diego, CA, USA), anti-CD 54 Fluorescein isothiocyanate (FITC), anti-CD105 APC, anti-HLA-ABC FITC (Invitrogen, Carlsbad, CA, USA), anti-CD14 FITC, anti-CD29 PE, anti-CD34 APC, anti-CD44 PE, anti-CD73 PE, anti-HLA-ABC FITC, anti-HLA-DR FITC (BD Pharmingen, San Diego, CA, USA), IgG2a FITC isotype control antibody, IgG1 PE isotype control antibody, IgG1 APC isotype control antibody (Miltenyi Biotech). For surface staining, cells were harvested by trypsinization for two minutes at 37°C. After centrifugation, supernatant was aspirated then antibodies were added and incubated for 30 min at 4°C in dark. Cells were then washed with PBS containing 0.5% BSA and 2 mM EDTA. 100,000 cells per sample were analyzed using a Accuri C6 flow cytometer (Accuri cytometers, Ann Arbor, MI, USA), and FlowJo software version 7.2.5 (Tree Star, Ashland, OR, USA). BMSCs from 4 MM patients and 4 normal marrow were analyzed.
Fold-induction of NF-κB activity was determined by phosphoimage quantification of enhanced NF-κB activity over constitutive activity, which was assigned an arbitrary value of one. Observed differences between MM and non-MM BMSCs were assessed for statistical significance using either Student's t-test or Mann-Whitney test depending on whether the normality assumption for the distribution of the data was reasonable (GFP expression, BAFF and APRIL protein levels, and the differential expression of 27 cytokines) or not (fold change in NF-κB activity and BAFF and APRIL mRNA levels). All tests were performed as a two-sided test, and the observed significance level, i.e. p-value, less than 0.05 was considered to indicate statistical significance of the observed differences
Grant Support: Predoctoral NIH Fellowship in Hematology Research T32-HL07899 and NIH individual F30-AG029714-02 (S. Markovina), NIH grant R01-CA08106, Multiple Myeloma Research Foundation Senior Investigator Grant, University of Wisconsin Trillium Foundation Grant, Shaw Scientist Award from Milwaukee Foundation (S. Miyamoto), NIH/NHLBI K08 HL081076 from NHLBI, NIH, University of Wisconsin Carbone Cancer Center Trillium Fund for Multiple Myeloma (P. Hematti), P30 CA014520 from NCI, NIH (K. Kim).
We thank the Miyamoto lab members for helpful discussion, and the Department of Hematology Clinical Trials Staff for help with IRB protocols and sample acquisition. We also thank Richard Burgess, PhD for his expert guidance in the purification of the stromal derived factor.
- Marx J: Cancer biology. All in the stroma: cancer's Cosa Nostra. Science. 2008, 320: 38-41. 10.1126/science.320.5872.38View ArticlePubMedGoogle Scholar
- Olumi AF, Grossfeld GD, Hayward SW, Carroll PR, Tlsty TD, Cunha GR: Carcinoma-associated fibroblasts direct tumor progression of initiated human prostatic epithelium. Cancer Res. 1999, 59: 5002-5011.PubMedGoogle Scholar
- Weaver VM, Petersen OW, Wang F, Larabell CA, Briand P, Damsky C, Bissell MJ: Reversion of the malignant phenotype of human breast cells in three-dimensional culture and in vivo by integrin blocking antibodies. J Cell Biol. 1997, 137: 231-245. 10.1083/jcb.137.1.231PubMed CentralView ArticlePubMedGoogle Scholar
- Broxterman HJ, Georgopapadakou NH: Anticancer therapeutics: a surge of new developments increasingly target tumor and stroma. Drug Resist Updat. 2007, 10: 182-193. 10.1016/j.drup.2007.07.001View ArticlePubMedGoogle Scholar
- Hideshima T, Mitsiades C, Tonon G, Richardson PG, Anderson KC: Understanding multiple myeloma pathogenesis in the bone marrow to identify new therapeutic targets. Nat Rev Cancer. 2007, 7: 585-598. 10.1038/nrc2189View ArticlePubMedGoogle Scholar
- Landowski TH, Olashaw NE, Agrawal D, Dalton WS: Cell adhesion-mediated drug resistance (CAM-DR) is associated with activation of NF-kappa B (RelB/p50) in myeloma cells. Oncogene. 2003, 22: 2417-2421. 10.1038/sj.onc.1206315View ArticlePubMedGoogle Scholar
- Mitsiades CS, Mitsiades NS, McMullan CJ, Poulaki V, Shringarpure R, Akiyama M, Hideshima T, Chauhan D, Joseph M, Libermann TA: Inhibition of the insulin-like growth factor receptor-1 tyrosine kinase activity as a therapeutic strategy for multiple myeloma, other hematologic malignancies, and solid tumors. Cancer Cell. 2004, 5: 221-230. 10.1016/S1535-6108(04)00050-9View ArticlePubMedGoogle Scholar
- Hideshima T, Chauhan D, Hayashi T, Podar K, Akiyama M, Gupta D, Richardson P, Munshi N, Anderson KC: The biological sequelae of stromal cell-derived factor-1 alpha in multiple myeloma. Mol Cancer Ther. 2002, 1: 539-544.View ArticlePubMedGoogle Scholar
- Anderson KC: Targeted therapy of multiple myeloma based upon tumor-microenvironmental interactions. Exp Hematol. 2007, 35: 155-162. 10.1016/j.exphem.2007.01.024View ArticlePubMedGoogle Scholar
- Annunziata CM, Davis RE, Demchenko Y, Bellamy W, Gabrea A, Zhan F, Lenz G, Hanamura I, Wright G, Xiao W: Frequent engagement of the classical and alternative NF-kappaB pathways by diverse genetic abnormalities in multiple myeloma. Cancer Cell. 2007, 12: 115-130. 10.1016/j.ccr.2007.07.004PubMed CentralView ArticlePubMedGoogle Scholar
- Keats JJ, Fonseca R, Chesi M, Schop R, Baker A, Chng WJ, Van Wier S, Tiedemann R, Shi CX, Sebag M: Promiscuous mutations activate the noncanonical NF-kappaB pathway in multiple myeloma. Cancer Cell. 2007, 12: 131-144. 10.1016/j.ccr.2007.07.003PubMed CentralView ArticlePubMedGoogle Scholar
- Kyle RA, Rajkumar SV: Multiple myeloma. Blood. 2008, 111: 2962-2972. 10.1182/blood-2007-10-078022PubMed CentralView ArticlePubMedGoogle Scholar
- Mulligan G, Mitsiades C, Bryant B, Zhan F, Chng WJ, Roels S, Koenig E, Fergus A, Huang Y, Richardson P: Gene expression profiling and correlation with outcome in clinical trials of the proteasome inhibitor bortezomib. Blood. 2007, 109: 3177-3188. 10.1182/blood-2006-09-044974View ArticlePubMedGoogle Scholar
- Stewart AK, Bergsagel PL, Greipp PR, Dispenzieri A, Gertz MA, Hayman SR, Kumar S, Lacy MQ, Lust JA, Russell SJ: A practical guide to defining high-risk myeloma for clinical trials, patient counseling and choice of therapy. Leukemia. 2007, 21: 529-534. 10.1038/sj.leu.2404516View ArticlePubMedGoogle Scholar
- Bloem AC, Lamme T, de Smet M, Kok H, Vooijs W, Wijdenes J, Boom SE, Lokhorst HM: Long-term bone marrow cultured stromal cells regulate myeloma tumour growth in vitro: studies with primary tumour cells and LTBMC-dependent cell lines. Br J Haematol. 1998, 100: 166-175. 10.1046/j.1365-2141.1998.00517.xView ArticlePubMedGoogle Scholar
- Lokhorst HM, Lamme T, de Smet M, Klein S, de Weger RA, van Oers R, Bloem AC: Primary tumor cells of myeloma patients induce interleukin-6 secretion in long-term bone marrow cultures. Blood. 1994, 84: 2269-2277.PubMedGoogle Scholar
- Uchiyama H, Barut BA, Mohrbacher AF, Chauhan D, Anderson KC: Adhesion of human myeloma-derived cell lines to bone marrow stromal cells stimulates interleukin-6 secretion. Blood. 1993, 82: 3712-3720.PubMedGoogle Scholar
- Arnulf B, Lecourt S, Soulier J, Ternaux B, Lacassagne MN, Crinquette A, Dessoly J, Sciaini AK, Benbunan M, Chomienne C: Phenotypic and functional characterization of bone marrow mesenchymal stem cells derived from patients with multiple myeloma. Leukemia. 2007, 21: 158-163. 10.1038/sj.leu.2404466View ArticlePubMedGoogle Scholar
- Faid L, Van Riet I, De Waele M, Facon T, Schots R, Lacor P, Van Camp B: Adhesive interactions between tumour cells and bone marrow stromal elements in human multiple myeloma. Eur J Haematol. 1996, 57: 349-358. 10.1111/j.1600-0609.1996.tb01392.xView ArticlePubMedGoogle Scholar
- Gregoretti MG, Gottardi D, Ghia P, Bergui L, Merico F, Marchisio PC, Caligaris-Cappio F: Characterization of bone marrow stromal cells from multiple myeloma. Leuk Res. 1994, 18: 675-682. 10.1016/0145-2126(94)90067-1View ArticlePubMedGoogle Scholar
- Wallace SR, Oken MM, Lunetta KL, Panoskaltsis-Mortari A, Masellis AM: Abnormalities of bone marrow mesenchymal cells in multiple myeloma patients. Cancer. 2001, 91: 1219-1230. 10.1002/1097-0142(20010401)91:7<1219::AID-CNCR1122>3.0.CO;2-1View ArticlePubMedGoogle Scholar
- Zdzisinska B, Bojarska-Junak A, Dmoszynska A, Kandefer-Szerszen M: Abnormal cytokine production by bone marrow stromal cells of multiple myeloma patients in response to RPMI8226 myeloma cells. Arch Immunol Ther Exp (Warsz). 2008,Google Scholar
- Zdzisinska B, Walter-Croneck A, Dmoszynska A, Kandefer-Szerszen M: Matrix metalloproteinase and cytokine production by bone marrow adherent cells from multiple myeloma patients. Arch Immunol Ther Exp (Warsz). 2006, 54: 289-296. 10.1007/s00005-006-0033-zView ArticleGoogle Scholar
- Corre J, Mahtouk K, Attal M, Gadelorge M, Huynh A, Fleury-Cappellesso S, Danho C, Laharrague P, Klein B, Reme T, Bourin P: Bone marrow mesenchymal stem cells are abnormal in multiple myeloma. Leukemia. 2007, 21: 1079-1088.PubMed CentralPubMedGoogle Scholar
- Garayoa M, Garcia JL, Santamaria C, Garcia-Gomez A, Blanco JF, Pandiella A, Hernandez JM, Sanchez-Guijo FM, del Canizo MC, Gutierrez NC, San Miguel JF: Mesenchymal stem cells from multiple myeloma patients display distinct genomic profile as compared with those from normal donors. Leukemia. 2009, 23: 1515-1527. 10.1038/leu.2009.65View ArticlePubMedGoogle Scholar
- Cao Y, Karin M: NF-kappaB in mammary gland development and breast cancer. J Mammary Gland Biol Neoplasia. 2003, 8: 215-223. 10.1023/A:1025905008934View ArticlePubMedGoogle Scholar
- Karin M: Nuclear factor-kappaB in cancer development and progression. Nature. 2006, 441: 431-436. 10.1038/nature04870View ArticlePubMedGoogle Scholar
- Bharti AC, Shishodia S, Reuben JM, Weber D, Alexanian R, Raj-Vadhan S, Estrov Z, Talpaz M, Aggarwal BB: Nuclear factor-kappaB and STAT3 are constitutively active in CD138+ cells derived from multiple myeloma patients, and suppression of these transcription factors leads to apoptosis. Blood. 2004, 103: 3175-3184. 10.1182/blood-2003-06-2151View ArticlePubMedGoogle Scholar
- Mitsiades CS, Mitsiades N, Poulaki V, Schlossman R, Akiyama M, Chauhan D, Hideshima T, Treon SP, Munshi NC, Richardson PG, Anderson KC: Activation of NF-kappaB and upregulation of intracellular anti-apoptotic proteins via the IGF-1/Akt signaling in human multiple myeloma cells: therapeutic implications. Oncogene. 2002, 21: 5673-5683. 10.1038/sj.onc.1205664View ArticlePubMedGoogle Scholar
- Perkins ND: Integrating cell-signalling pathways with NF-kappaB and IKK function. Nat Rev Mol Cell Biol. 2007, 8: 49-62. 10.1038/nrm2083View ArticlePubMedGoogle Scholar
- Pham LV, Tamayo AT, Yoshimura LC, Lo P, Ford RJ: Inhibition of constitutive NF-kappa B activation in mantle cell lymphoma B cells leads to induction of cell cycle arrest and apoptosis. J Immunol. 2003, 171: 88-95.View ArticlePubMedGoogle Scholar
- Hideshima T, Ikeda H, Chauhan D, Okawa Y, Raje N, Podar K, Mitsiades C, Munshi NC, Richardson PG, Carrasco RD, Anderson KC: Bortezomib induces canonical nuclear factor-kappaB activation in multiple myeloma cells. Blood. 2009, 114: 1046-1052. 10.1182/blood-2009-01-199604PubMed CentralView ArticlePubMedGoogle Scholar
- Markovina S, Callander NS, O'Connor SL, Kim J, Werndli JE, Raschko M, Leith CP, Kahl BS, Kim K, Miyamoto S: Bortezomib-resistant nuclear factor-kappaB activity in multiple myeloma cells. Mol Cancer Res. 2008, 6: 1356-1364. 10.1158/1541-7786.MCR-08-0108PubMed CentralView ArticlePubMedGoogle Scholar
- Yang DT, Young KH, Kahl BS, Markovina S, Miyamoto S: Prevalence of bortezomib-resistant constitutive NF-kappaB activity in mantle cell lymphoma. Mol Cancer. 2008, 7: 40- 10.1186/1476-4598-7-40PubMed CentralView ArticlePubMedGoogle Scholar
- Amit-Vazina M, Shishodia S, Harris D, Van Q, Wang M, Weber D, Alexanian R, Talpaz M, Aggarwal BB, Estrov Z: Atiprimod blocks STAT3 phosphorylation and induces apoptosis in multiple myeloma cells. Br J Cancer. 2005, 93: 70-80. 10.1038/sj.bjc.6602637PubMed CentralView ArticlePubMedGoogle Scholar
- Trivedi P, Hematti P: Derivation and immunological characterization of mesenchymal stromal cells from human embryonic stem cells. Exp Hematol. 2008, 36: 350-359.PubMed CentralPubMedGoogle Scholar
- Dominici M, Le Blanc K, Mueller I, Slaper-Cortenbach I, Marini F, Krause D, Deans R, Keating A, Prockop D, Horwitz E: Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy. 2006, 8: 315-317. 10.1080/14653240600855905View ArticlePubMedGoogle Scholar
- Noborio-Hatano K, Kikuchi J, Takatoku M, Shimizu R, Wada T, Ueda M, Nobuyoshi M, Oh I, Sato K, Suzuki T: Bortezomib overcomes cell-adhesion-mediated drug resistance through downregulation of VLA-4 expression in multiple myeloma. Oncogene. 2009, 28: 231-242. 10.1038/onc.2008.385View ArticlePubMedGoogle Scholar
- Kline M, Donovan K, Wellik L, Lust C, Jin W, Moon-Tasson L, Xiong Y, Witzig TE, Kumar S, Rajkumar SV, Lust JA: Cytokine and chemokine profiles in multiple myeloma; significance of stromal interaction and correlation of IL-8 production with disease progression. Leuk Res. 2007, 31: 591-598. 10.1016/j.leukres.2006.06.012View ArticlePubMedGoogle Scholar
- Lauta VM: A review of the cytokine network in multiple myeloma: diagnostic, prognostic, and therapeutic implications. Cancer. 2003, 97: 2440-2452. 10.1002/cncr.11072View ArticlePubMedGoogle Scholar
- Berchtold CM, Chen KS, Miyamoto S, Gould MN: Perillyl alcohol inhibits a calcium-dependent constitutive nuclear factor-kappaB pathway. Cancer Res. 2005, 65: 8558-8566. 10.1158/0008-5472.CAN-04-4072View ArticlePubMedGoogle Scholar
- Miyamoto S, Seufzer BJ, Shumway SD: Novel IkappaB alpha proteolytic pathway in WEHI231 immature B cells. Mol Cell Biol. 1998, 18: 19-29.PubMed CentralView ArticlePubMedGoogle Scholar
- O'Connor S, Markovina S, Miyamoto S: Evidence for a phosphorylation-independent role for Ser 32 and 36 in proteasome inhibitor-resistant (PIR) IkappaBalpha degradation in B cells. Exp Cell Res. 2005, 307: 15-25. 10.1016/j.yexcr.2005.02.015View ArticlePubMedGoogle Scholar
- O'Connor S, Shumway SD, Amanna IJ, Hayes CE, Miyamoto S: Regulation of constitutive p50/c-Rel activity via proteasome inhibitor-resistant IkappaBalpha degradation in B cells. Mol Cell Biol. 2004, 24: 4895-4908. 10.1128/MCB.24.11.4895-4908.2004PubMed CentralView ArticlePubMedGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.